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Self-Measurement of Blood Pressure at Home Reduces the
Need for Antihypertensive Drugs
A Randomized, Controlled Trial
Willem J. Verberk, Abraham A. Kroon, Jacques W.M. Lenders, Alfons G.H. Kessels,
Gert A. van Montfrans, Andries J. Smit, Paul-Hugo M. van der Kuy, Patricia J. Nelemans,
Roger J.M.W. Rennenberg, Diederick E. Grobbee, Frank W. Beltman, Manuela A. Joore,
Danie¨lle E.M. Brunenberg, Carmen Dirksen, Theo Thien, Peter W. de Leeuw;
for the Home Versus Office Measurement, Reduction of Unnecessary Treatment Study Investigators
Abstract—It is still uncertain whether one can safely base treatment decisions on self-measurement of blood pressure. In the
present study, we investigated whether antihypertensive treatment based on self-measurement of blood pressure leads to the
use of less medication without the loss of blood pressure control. We randomly assigned 430 hypertensive patients to receive
treatment either on the basis of self-measured pressures (n216) or office pressures (OPs; n214). During 1-year follow-up,
blood pressure was measured by office measurement (10 visits), ambulatory monitoring (start and end), and self-measurement
(8 times, self-pressure group only). In addition, drug use, associated costs, and degree of target organ damage (echocardi-
ography and microalbuminuria) were assessed. The self-pressure group used less medication than the OP group (1.47 versus
2.48 drug steps; P0.001) with lower costs ($3222 versus $4420 per 100 patients per month; P0.001) but without
significant differences in systolic and diastolic OP values (1.6/1.0 mm Hg; P0.25/0.20), in changes in left ventricular mass
index (6.5 g/m2 versus 5.6 g/m2; P0.72), or in median urinary microalbumin concentration (1.7 versus 1.5 mg per
24 hours; P0.87). Nevertheless, 24-hour ambulatory blood pressure values at the end of the trial were higher in the
self-pressure than in the OP group: 125.9 versus 123.8 mm Hg (P0.05) for systolic and 77.2 versus 76.1 mm Hg (P0.05)
for diastolic blood pressure. These data show that self-measurement leads to less medication use than office blood pressure
measurement without leading to significant differences in OP values or target organ damage. Ambulatory values, however,
remain slightly elevated for the self-pressure group. (Hypertension. 2007;50:1019-1025.)
Key Words: blood pressure  hypertension  self-measurements  home monitoring
 ambulatory blood pressure measurement  treatment
As indications for lowering blood pressure (BP) becomeincreasingly stringent, the associated medication use and
costs rise markedly.1 This calls for proper diagnosis and careful
selection of patients in whom treatment is really indicated. In this
respect, conventional office BP measurements (OBPMs) have
disadvantages, because they can easily elicit a white-coat effect,
overestimation of a patient’s BP,2 and unnecessary drug pre-
scription. Self-BP measurements (SBPMs) are less liable to the
white-coat effect3 and may provide a more reliable estimate of a
patient’s “true” BP. In addition, SBPM correlates better with the
development of target organ damage (TOD) than OBPM4–6 and
for the occurrence of cardiovascular complications.7,8 Therefore,
SBPM has the potential to identify subjects that may not need
treatment. This could reduce drug use and lead to considerable
costs savings. The Home versus Office Measurement, Reduction
of Unnecessary treatment Study (HOMERUS) was designed to
determine whether treatment based on SBPM leads to a de-
creased drug prescription without an impaired BP control and
TOD as compared with treatment based on OBPM.
Methods
The design of the HOMERUS has been described in detail else-
where.9 Briefly, HOMERUS is a multicenter, prospective, random-
Continuing medical education (CME) credit is available for this article. Go to http://cme.ahajournals.org to take the quiz.
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ized, double-blind trial with a parallel-group design. Patients, aged
18 years whose office BP was 139 mm Hg systolic and/or
89 mm Hg diastolic were randomly allocated to either the self-
pressure (SP) group or to the office pressure (OP) group using a
procedure of minimization.10,11 If randomly assigned to the SP
group, the patient was instructed to start self-measurements of BP at
home. In this group, stepwise antihypertensive treatment was guided
by the results of SBPM. In the OP group, stepwise treatment was
based on office readings. The prescribing physician was kept blinded
from random assignment and, therefore, remained unaware of
whether the patient was treated according to OBPM or SBPM values.
To maintain blinding during follow-up, medication was prescribed
and, if necessary, adapted by a physician at the coordinating center
who based his treatment decisions on the average OBPM or SBPM
values. Patients picked up their treatment from their own pharmacist,
who had been extensively informed about the trial and the impor-
tance of handing out the precise number of pills that were prescribed.
Patients were asked not to tell their physician to which group they
belonged. In accordance with recommendations at the time that this
study started, the target BP was set at 140-mm Hg systolic and
90-mm Hg diastolic and the lower limit at 120-mm Hg systolic and
80-mm Hg diastolic for both groups. At entry into the study, any
existing antihypertensive therapy was discontinued whenever possi-
ble, and patients entered a placebo run-in period of 4 weeks’ duration
before study treatment was initiated. If the treating physician
considered interruption of treatment to be too hazardous, the patient
was switched immediately to trial medication. Twenty-four–hour
ambulatory BP monitoring (ABPM), as a reference standard, and
assessment of TOD (heart and kidney) took place at the end of the
run-in period and at the end of the trial. Final results of the trial were
analyzed in 2 domains: medication use and treatment costs and
degree of BP control and TOD. The study was approved by an
institutional review committee. Informed consent in accordance with
the Declaration of Helsinki was obtained from all of the patients
before entering the study, and the procedures followed were in
accordance with institutional guidelines.
BP Measurements
At each visit, 3 consecutive OBPMs were performed in the hospital
or at the general practitioner’s clinic. Patients of the SP group started
SBPM 3 weeks after study entry. SBPM was performed 6 times a
day (3 in the morning and 3 in the evening) for a 7-day period before
every visit. Both OBPM and SBPM were always performed in the
nondominant arm in sitting position after 5 minutes of rest using
the same fully automated device (Omron HEM-705 CP).12 In
addition, ABPM was performed with a Spacelabs automatic device
at the start and end of the trial. Measurements were taken every 15
minutes between 7 AM and 11 PM and every 30 minutes at night. The
average daytime ABPM value was calculated from 9 AM and 9 PM
hour on the first day without the initial hour. Average nocturnal
ABPM was determined from 1 AM and 6 AM.
Additional Measurements
Treatment Costs
Treatment costs consisted of medication costs (ie, drug costs and
pharmacist fee) and costs of the BP monitor. Medication costs were
computed for each drug on each visit. Medication prices from May
2005 were taken for analysis. In the SP group, the costs of the BP
monitor were calculated using the annuity method with a deprecia-
tion period of 3 years, an interest rate of 4.5%, and maintenance costs
of 8% of the purchase price. Total treatment costs are reported in
US$ (1 US$ is 0.76€ at the January 2004 conversion rate).
Adherence to Treatment
At each visit, patients had to take their medication bottles to the
clinic where the physician or nurse counted the number of pills left
in the bottle in the presence of the patient. Feedback was given only
when the number of pills left was extremely high. The scores were
transmitted to the coordinating center, where the number of pre-
scribed pills was registered so that intake could be calculated.
Adverse Effects of Medication
In a subscale of the Bulpitt questionnaire,13 symptoms of hyperten-
sion and adverse effects of medication were addressed. This was
performed in 356 patients (179 from the SP group and 177 from the
OP group) who were included before May 1, 2003.
Statistical Considerations
Data were analyzed according to the intention-to-treat principle. The
last observation carried forward method was applied for missing
values when data of 2 consecutive visits were available. Differ-
ences in BP between the 2 randomized groups were analyzed by a
multivariate analysis adjusting for baseline BP values, center, age,
gender, body mass index, smoking, antihypertensive drugs at base-
line, run-in period, and setting of patient recruitment. Other between-
group comparisons involved the following statistical methods: Stu-
dent’s t test, Mann-Whitney (when data were not normally
distributed), or 2 for proportions. A 2-sided P0.05 was taken as
statistical significance. All of the statistical calculations were per-
formed using SPSS version 12.0 (SPSS, Inc).
Results
Altogether, 459 patients met the inclusion criteria and were
considered eligible for the study. Of these, 29 did not start
trial therapy because they withdrew or refused consent for
various reasons. Consequently, 430 patients entered the study
after a 4-week run-in period and started trial medication
(Figure 1). Baseline characteristics at inclusion were compa-
rable for the 2 groups (Table 1).
During the trial, 46 patients dropped out (OP group: 27; SP
group: 19) because they withdrew consent (n44), had an
adverse event (n1), or became pregnant (n1). Reasons for
withdrawing consent were that patients felt uncomfortable
with the blinded medication, complained about adverse ef-
fects, found the frequent visits to the hospital too cumber-
some, or thought that the additional examinations might be
too hazardous. Patients who dropped out from the study did
not differ in any characteristic from patients who completed
follow-up either between or within groups.
Median follow-up time was 351 days (interquartile range:
336 to 366 days) for the OP group and 354 days (interquartile
range: 340 to 369 days) for the SP group. Twenty patients (10
in each group) had no run-in period and switched immedi-
ately to the trial medication.
Figure 1. Flowchart of the trial.
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Medication Use and Costs
Figure 2 shows that more patients from the SP group than
from the OP group could permanently stop their medication
because their BP values came below the present targets
(10.7% versus 1.9%; log rank:0.0001). Moreover, in the SP
group, a greater proportion of patients reached a stable
treatment level (treatment unchanged during the remaining
part of the study) than in the OP group (54.0% versus 48.0%;
log rank: 0.0001). On average, the SP group used 1 drug or
1 dose less in comparison with the OP group (P0.001).
Please see Table S1, available online at http://hyper.
ahajournals.org, for more detailed information regarding
medication use.
Significant differences for certain drugs were mainly
caused by the fact that patients in the OP group were at a
higher level of the treatment schedule. At the end of the trial,
significantly more patients in the OP group than in the SP
group received atenolol because of adverse effects to lisino-
pril (mostly dry cough).
Medication costs during the whole study amounted to
$4147 in the OP group and $3023 in the SP group per 100
patients for 1 month of treatment, resulting in a saving in
medication costs of $1124 (P0.001). With inclusion of the
fees for pharmacist, costs amounted to $4420 and $3222
(P0.001) for the OP and SP group, respectively. The profit
in the SP group is partially offset by the cost of the BP device,
which was $490 for 100 patients for 1 month. However, when
corrected for these costs, the SP group still has lower
treatment costs than the OP group (P0.03). The total
number of visits in the trial was similar in the SP and OP
group, 2012 versus 2066, with a mean charge of $70 and $71
for the OP and SP group, respectively.
BP Control
Figure 3 illustrates the time course of BP patterns. Systolic
OBPM increased after visit 1 when the run-in period started
and regular antihypertensive treatment was discontinued. At
visit 3, more patients were hypertensive according to their
systolic BP than to their diastolic BP (n391 versus n342).
Both groups showed almost similar BP patterns throughout
the trial. Although SBPM followed the same pattern during
follow-up as OBPM, at every visit SBPM was significantly
lower than OBPM (P0.001). Of the 42 SBPMs that had to
Table 1. Distribution of Clinical Characteristics at Inclusion
Variable
Total
(n430)
OP Group
(n216)
SP Group
(n214)
Males (%), n 236 (55) 118 (55) 118 (55)
Age (SD), y 55 (11) 55 (11) 55 (11)
BMI (SD), kg/m2 28 (4) 28 (5) 28 (4)
Smoking, n (%) 77 (18) 42 (19) 35 (16)
Alcohol, n (%) 329 (77) 169 (78) 160 (75)
Glucose (SD), mmol/L 5.5 (1) 5.4 (1) 5.6 (1)
Cholesterol (SD), mmol/L 5.7 (1) 5.7 (1) 5.7 (1)
Creatinine (SD), mol/L 82 (16) 82 (14) 82 (17)
Microalbuminuria, mg/24 h* 10.3 10.6 10.0
Treatment status, n (%)
Untreated 132 (31) 64 (30) 68 (32)
1 drug 160 (37) 85 (39) 75 (35)
2 drugs 103 (24) 50 (23) 53 (25)
3 drugs 35 (8) 17 (8) 18 (8)
Previous antihypertensive
treatment, n (%)
Diuretics 116 (27) 55 (25) 61 (29)
ACE inhibitors 114 (27) 59 (27) 55 (26)
-Blockers 120 (28) 57 (26) 63 (29)
Calcium channel blockers 51 (12) 27 (13) 24 (11)
Angiotensin II receptor
blockers
65 (15) 35 (16) 30 (14)
-Blockers 8 (2) 6 (3) 2 (1)
BMI indicates body mass index; ACE, angiotensin-converting enzyme.
*Results are given as medians.
Figure 2. Graph showing the proportion of patients in both
treatment groups in whom medication could be discontinued
(left) or in whom a stable treatment was reached at target pres-
sure during 1 year of follow-up.
Figure 3. Graph showing time course of office BP (top), self-
measured BP (middle), and mean 24-hour ambulatory BP in
the office measurements group (E) and the self-measurement
group (F).
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be performed before each visit, patients measured their BP on
average 39 times. Table 2 illustrates OBPM, SBPM, and
ABPM values at the end of the run-in period and at the end
of the trial. Although OBPM values were similar at the end of
the trial, ABPM values were significantly lower in the OP
group than in the SP group.
In the OP group, 409 treatment decisions (24%) were based
on elevated systolic BP only, 48 (3%) on elevated diastolic
BP only, and 699 (41%) on an elevation of both systolic and
diastolic BP. In the SP group, these numbers were 357 (21%),
34 (2%), and 398 (23%), respectively. Both for systolic and
diastolic BP, no significant differences in OBPM between the
randomly assigned groups were found at the end of the trial
for either absolute BP values (P0.25 and P0.20) or for
changes in BP (P0.77 and P0.14).
Refractory or Resistant Hypertension
The number of patients with refractory or resistant hyperten-
sion (defined as the use of 3 different antihypertensives,
whereas OBPM is still 140 mm Hg systolic and/or
90 mm Hg diastolic) was significantly higher in the OP group
than in the SP group (38 [18%] versus 19 [9%]; P0.01).
Target BP
At the end of the trial, 106 patients (50%) in the OP group had
an OBPM value 140/90 mm Hg, whereas in the SP group,
160 patients (74%) had reached a final SBPM value that was
140/90 mm Hg (P0.001). If we took the number of
patients from the SP group who reached a SBPM value of
135/85 mm Hg, there were 112 patients (52%) who reached
this target. At the last visit, 18 patients (8%) from the SBPM
group had a normal OBPM but an elevated SBPM (masked
hypertension).
TOD
Changes in left ventricular mass index were similar in both
groups: 6.51.7 g/m2 (from 98.3 to 91.8 g/m2) versus
5.61.7 g/m2 (from 96.4 to 90.8 g/m2) for the OP and SP
group, respectively (P0.72). Median changes in urinary
microalbumin concentration were also similar: from 10.0 to
8.3 mg per 24 hours and from 10.7 to 9.2 mg per 24 hours for
the OP and SP group, respectively (P0.87). Within-group
reductions in left ventricular mass index and microalbumin-
uria concentrations were significant for both randomly as-
signed groups (P0.001). No significant differences between
groups were found for other laboratory variables.
Pill Count
Pill counts, which were assessed in all of the patients,
indicated that medication intake was similar in both arms:
88.1% in the OP group versus 87.3% in the SP group
(P0.62).
Adverse Effects
For reported frequency of symptoms and adverse effects per
visit, please see Table S2. Headaches, joint complaints,
flushing of face or neck, light-headedness, and sleepiness
were the most frequently mentioned symptoms (35%).
Table 2. BP Values at the End of the Run-In Period and at the End of the Trial
BP Time
OP Group (n214),
meanSD, mm Hg
SP Group (n216),
meanSD, mm Hg
Difference Mean,
OPSP (95% CI) P
OBPM systolic End run-in 165.120.8 166.219.3 1.0 (4.8 to 2.8) 0.46
End trial 142.220.0 143.818.4 1.6 (5.3 to 2.0) 0.29
OBPM diastolic End run-in 97.810.8 97.19.9 0.7 (1.2 to 2.7) 0.57
End trial 84.39.6 85.410.4 1.0 (2.9 to 0.9) 0.13
SBPM systolic End run-in NA 156.116.9 NA NA
End trial NA 134.312.2 NA NA
SBPM diastolic End run-in NA 92.89.0 NA NA
End trial NA 80.98.1 NA NA
ABPM 24-h systolic End run-in 143.413.5 143.713.8 0.4 (3.0 to 2.3) 0.84
End trial 123.812.2 125.99.0 2.1 (4.3 to 0.0) 0.04
ABPM 24-h diastolic End run-in 88.48.8 88.19.7 0.3 (1.5 to 2.1) 0.93
End trial 76.17.9 77.27.4 1.1 (2.7 to 0.4) 0.05
ABPM day systolic End run-in 149.514.5 149.314.8 0.1 (2.8 to 3.0) 0.78
End trial 129.112.8 131.210.7 2.2 (4.5 to 0.2) 0.03
ABPM day diastolic End run-in 93.69.3 92.710.5 1.0 (1.0 to 2.9) 0.48
End trial 80.48.4 81.68.6 1.2 (2.9 to 0.5) 0.05
ABPM night systolic End run-in 127.615.8 127.914.5 0.3 (3.3 to 2.7) 0.93
End trial 110.112.5 112.310.1 2.2 (4.5 to 0.1) 0.03
ABPM night diastolic End run-in 76.110.4 76.210.5 0.1 (2.2 to 2.0) 0.81
End trial 65.58.8 66.47.5 1.0 (2.6 to 0.7) 0.14
NA indicates not applicable. BP values are adjusted for baseline value, sex, age, body mass index, smoking, region of inclusion,
and for a run-in period (yes or no). Bold printed indicates a significant between-group difference (P0.05). All within-group changes
were significant (P0.001).
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Discussion
Our results show that adjustment of antihypertensive therapy
based on SBPM can reduce the number of drugs without loss
of OBPM control or an increase in the number of refractory
hypertensive patients. Yet, a tendency toward slightly worse
ABPM control was noted in patients of the SP group as
compared with those of the OP group. Despite the latter,
regression of TOD was comparable in the 2 groups. In
addition, patients in the SP group had a similar chance to
reach the target BP value as those in the OP group when this
target was set at 135/85 mm Hg for SBPM. Finally, signifi-
cantly more patients in the SP group could permanently stop
their antihypertensive medication, suggesting that SBPM may
be a valuable tool to prevent unnecessary drug prescription.
This study must be interpreted within the context of its
limitations. BP measurements were not performed with a
memory-equipped device, thus leaving room for observer
bias; patients may have measured BP more often than needed
and selected 3 preferred measurements. In some practices,
OBPM was performed by a nurse instead of a physician,
which may have resulted in lower BP values.14 Hence, some
dilution cannot entirely be excluded, although patients were
equally divided between the 2 groups in these practices.
The present study chose to take 140/90 mm Hg as the
target of treatment for SBPM instead of the 135/85 mm Hg,
which is presently recommended.15 This may have caused
some undertreatment in the SP group relative to the OP
group. However, at the time the protocol for HOMERUS was
written, there was no agreement on what should be the upper
limit for SBPM,16 because only some cross-sectional stud-
ies17–22 and 1 longitudinal study23 had addressed this subject
by then. Second, the guidelines that recommend 135/
85 mm Hg as the threshold for SBPM prescribe that OBPM is
taken with a mercury sphygmomanometer and SBPM with an
oscillometric automatic device. In the present study, both
SBPM and OBPM have been performed with the same
oscillometric automatic device so that there were no differ-
ences in BP values caused by the device. Third, the recom-
mendations for OBPM prescribe that 2 measurements should
be performed.24 In the present study, 3 measurements have
been obtained, which generally leads to lower average OBPM
values, because the first measurement is usually higher than
subsequent ones.25 Lower OBPM values tend to dilute the
differences between OBPM and SBPM.
Recently, the results of the Treatment of Hypertension
based on home or Office blood Pressure (THOP) Trial26 were
published which showed that patients whose medical treat-
ment was based on SBPM had poorer OBPM and ABPM
values than patients in whom treatment was based on OBPM.
Although the THOP Trial seems largely similar to HOM-
ERUS, there are some important differences. Firstly, in the
THOP Trial, treatment was based on diastolic BP
(90 mm Hg) only, because at the time the World Health
Organization still defined hypertension exclusively on the
basis of diastolic BP. However, in the present study, more
patients were hypertensive according to their systolic BP than
to their diastolic BP at baseline. In addition, during follow-up,
a quarter of all treatment decisions were based on elevated
systolic BP only. For optimal management of hypertension, a
well-controlled systolic BP is important, because it correlates
significantly stronger with the risk of cardiovascular or
all-cause death27 than diastolic BP. Second, in the THOP
Trial, OBPMs were performed with a manual mercury sphyg-
momanometer, whereas an automatic device was applied for
SBPM. The use of different devices complicates comparisons
between both strategies, and, in addition, manual sphygmo-
manometers are more liable to observer bias.28 Third, in
HOMERUS, patients in the OP group did not perform SBPM.
Although this has the disadvantage that it is impossible to
keep the patient blinded for randomization, it certainly better
represents the normal clinical situation, which is important,
because SBPM influences a patients’ behavior.29
The cost-effectiveness of SBPM has also been evaluated in
the THOP Trial. Our study confirmed that a significant
reduction in medication intensity and costs can be reached.
The maximum difference in treatment costs was obtained at
the end of the study. When these costs were extrapolated to
the next year, this led to an even greater reduction in costs in
favor of the SP group.
At the end of the trial, ABPM values were higher in the SP
than in the OP group. Although this could mean that antihy-
pertensive treatment based on SBPM leads to worse BP
control as compared with OBPM-based treatment, we must
realize that the reproducibility of ABPM is limited.30 Al-
though differences in mean ABPM and OBPM values be-
tween both groups are small and perhaps not relevant for a
patient as an individual, these results cannot be ignored,
because even small differences can have serious conse-
quences with respect to cardiovascular complications in the
population at large. Indeed, a meta-analysis of individual data
for 1 million adults in 61 prospective studies showed that a
2-mm Hg–lower systolic BP value would eventually lead to a
10% lower stroke mortality and 7% lower mortality from
ischemic heart diseases or other vascular causes in middle-
age patients.31
From these results, one may be inclined to think that it is
better to base antihypertensive treatment on OBPM instead of
SBPM. However, we believe that the present article offers
several arguments that favor SBPM above OBPM. First of
all, when we apply a threshold of 135/85 mm Hg as the
treatment target in the SBPM patients, 52% actually reached
this goal, which is quite similar to the 50% of OBPM patients
who reached their target of 140/90 mm Hg OP. When using
135/85 mm Hg as a threshold value, there were 104 patients
in the SP group who did not reach the target BP. Let us
assume that these patients would need, on average, 1 addi-
tional treatment step to reach this target. If we consider the
most expensive step at any occasion (Lisinopril, $15 for 1
month of treatment), the necessary additional costs for
treatment would be 104$15$1560 for 1 month of treat-
ment. For the whole SP population, this would equal $1560/
216$7.22 per patient for 1 month of treatment. When added
to the $3023, this would increase total costs in the SP group
to $3745, which is still less than the $4147 for the OP group.
This, together with the fact that half of the patients from the
OP group also need additional treatment to reach their target
BP of 140/90 mm Hg, indicates that it is most likely that
treatment based on SBPM would lead to BP values similar to
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those in patients from the OP group with less medication. The
second argument for using SBPM is the presence of masked
hypertension, which is defined as a BP that is normal in the
office but elevated when measured at home.32 In the present
study, 18 patients (8%) from the SP group had this phenom-
enon at the last visit. Other studies have shown that these
patients have a similar risk of cardiovascular complications as
“true” subjects with hypertension. Third, there were signifi-
cantly less patients with refractory or resistant hypertension
in the SP group than in the OP group. Finally, both the OP
group and the SP group experienced a similar reduction in
TOD (heart and kidney), which would imply that the SP
group was not worse off.
Based on earlier data, one would expect that patients from
the SP group would be more adherent to their medication than
patients from the OP group, because SBPM increases pa-
tients’ awareness of their disease.33 However, the high overall
adherence rate in both treatment groups as observed in the
present study likely reflects some inherent motivation of
patients who are willing to participate in a clinical trial. In this
respect, SBPM had little additional value.
In conclusion, the findings in this randomized trial show
that, in a population of mild-to-moderate hypertensive sub-
jects without significant comorbidity, antihypertensive treat-
ment based on SBPM is not associated with worse OBPM
control, with more TOD, with an increased number of
refractory hypertensive patients, or with a lower chance of
reaching target BP as compared with treatment based on
OBPM. In addition, SBPM does lead to decreased use of
medication and, thus, less overall healthcare costs and ad-
verse effects. Therefore, our findings support the use of
SBPM in addition to OBPM in regular clinical care to
improve overall BP control and to prevent unnecessary
treatment prescriptions with associated healthcare costs.
However, because the ambulatory BP was less well con-
trolled in patients from the SP group than in patients from the
OP group, the present study did not provide hard evidence
that it is safe to base antihypertensive treatment on SBPM
readings. Because this can be partly ascribed to using a
threshold value of 140/90 mm Hg, we recommend the use of
the proposed values of 135 mm Hg systolic and 85 mm Hg
diastolic as the threshold values for normal SBPM.
Perspectives
Treatment based on SBPM using a threshold value of
140/90 mm Hg leads to less drug prescription than treatment
based on OBPM. However, this also leads to slightly higher
ABPM values that, in the long run and extended to a large
population, may still lead to an increase in cardiovascular
events. Therefore, large outcome trials with a longer follow-up
period are necessary to confirm or refute the significance of our
present findings. It should also be emphasized that our results are
applicable only to the specific population of hypertensive pa-
tients that we included in our trial. It would be worthwhile to
assess whether SBPM has the same implications in patients with
comorbid conditions, such as diabetes mellitus or renal impair-
ment, as well as in populations with a different racial back-
ground. Finally, the present data may serve as a starting point for
more elaborate cost-effectiveness studies and reimbursement of
BP monitoring devices.
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